Who Owns arGEN-X Company?

arGEN-X Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns arGEN-X?

Understanding arGEN-X's ownership is key to grasping its strategic direction. The company's journey includes a dual listing on Euronext Brussels in 2014 and Nasdaq in 2017, expanding its investor reach.

Founded in Belgium in 2008, arGEN-X focuses on autoimmune diseases and cancer using antibody technology. As of August 20, 2025, its market cap is around $40.01 billion, with shares on Nasdaq (ARGX) and Euronext Brussels.

Who owns arGEN-X?

arGEN-X SE was established in 2008 by a group of accomplished scientists and entrepreneurs: Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier. Tim Van Hauwermeiren, who continues to lead as Chief Executive Officer, has been instrumental since the company's inception, bringing over two decades of experience in general management and business development within the life sciences and consumer goods industries.

Founding Team Expertise

The company was founded by experienced scientists and entrepreneurs. Tim Van Hauwermeiren, the CEO, has extensive experience in life sciences and consumer goods.

Early Funding Success

A Series A funding round in 2009 secured €12.5 million. This capital was crucial for the company's initial development and operations.

Key Early Investors

Prominent early backers included Forbion Capital Partners and LSP (Life Sciences Partners). Omnes Capital also became a significant shareholder through multiple investments.

Strategic Vision

The founders aimed to address unmet medical needs with innovative antibody-based therapies. Their focus was on severe autoimmune diseases and cancer.

Technology Licensing

The company utilized technology that was licensed from Unilever. This provided a foundational platform for their therapeutic development.

Ownership Transparency

While specific founder equity percentages are not public, their significant stake is acknowledged. The company emphasizes a transparent ownership structure as a publicly traded entity.

The founders' collective vision was to tackle significant unmet medical needs by developing pioneering antibody-based therapies targeting severe autoimmune diseases and cancer. This ambition was supported by technology licensed from Unilever, providing a strong scientific basis for their endeavors. The early financial backing was substantial, with a Series A funding round in 2009 raising €12.5 million, led by influential early investors like Forbion Capital Partners and LSP. Omnes Capital also played a key role, investing €46 million across various funding rounds starting in 2009, which significantly shaped the company's initial ownership landscape. Although the precise initial equity stakes held by the founders are not publicly disclosed, their substantial ownership and alignment with shareholder interests are recognized as integral to the transparent ownership framework of the publicly traded organization. Understanding the Marketing Strategy of arGEN-X can provide further context on how these early foundations have been leveraged.

Founders and Early Ownership Structure

The initial ownership of arGEN-X was established by its founders and early investors who provided critical capital. This foundational support enabled the company to pursue its ambitious goals in developing novel therapies.

• Founders Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier established the company in 2008.
• The company's early development was significantly funded by a €12.5 million Series A round in 2009.
• Key early investors included Forbion Capital Partners and LSP (Life Sciences Partners).
• Omnes Capital became a major shareholder, investing €46 million across multiple funding rounds.
• The founders hold a substantial stake, contributing to a transparent ownership structure.

arGEN-X SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

arGEN-X's ownership journey began with its initial public offering on Euronext Brussels in July 2014, raising €40 million. This was followed by a significant listing on the Nasdaq Global Select Market in May 2017, which broadened its investor base and increased its public float.

Institutional investors are the dominant force in arGEN-X's ownership as of August 20, 2025, collectively holding over 60% of the company's stock. This substantial institutional backing indicates strong confidence in the company's future prospects and its Target Market of arGEN-X. The company has 770 institutional owners and shareholders, managing a total of 39,282,388 shares.

Key Institutional Holders

Several major institutions hold significant stakes in arGEN-X, influencing its strategic direction.

• FMR LLC: 5,423,508 shares (as of June 30, 2025)
• Price T Rowe Associates Inc /Md/: 4,979,976 shares (as of June 30, 2025)
• Janus Henderson Group Plc: 2,565,399 shares (as of June 30, 2025)
• Norges Bank Investment Management: 3.078% of shares (as of August 6, 2025)
• Wellington Management Co. LLP: 2.995% of shares (as of August 6, 2025)

arGEN-X PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of December 31, 2024, the arGEN-X Board of Directors comprises 10 individuals, with 1 Executive Director and 9 Non-Executive Directors. Peter K. Verhaeghe leads the board as Chairperson, while co-founder and CEO Tim Van Hauwermeiren represents the executive leadership.

The company's voting power is structured around a single class of ordinary shares, including those represented by American Depositary Shares (ADSs), with each share granting one vote. This ensures a clear one-share-one-vote principle, with no special rights attached to any particular shares. As of February 19, 2025, the total issued share capital was €6,099,085.70, representing 60,990,857 ordinary shares. Transparency in major shareholdings is maintained through a notification requirement to the Dutch Authority for the Financial Markets (AFM) for holdings of 3% or more. There have been no recent public reports of proxy battles or significant governance disputes, indicating a stable ownership and governance environment.

Understanding arGEN-X Ownership

The ownership structure of arGEN-X is characterized by a straightforward voting system and transparent disclosure requirements for significant stakes.

• One class of ordinary shares, including ADSs, each with one vote.
• No special voting rights or preferential share classes.
• Notification of holdings of 3% or more to the AFM.
• As of February 19, 2025, 60,990,857 ordinary shares were issued.
• The company's Mission, Vision & Core Values of arGEN-X guide its strategic direction.

arGEN-X Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent financial performance and strategic initiatives have significantly shaped the ownership trends for arGEN-X over the past few years. The company's robust growth, evidenced by substantial sales figures and strong cash reserves, has attracted increased institutional investment, indicating a growing confidence among major shareholders in its market position and future prospects.

Institutional investors now collectively hold over 60% of arGEN-X's stock, a testament to the company's market performance and promising pipeline. While there have been no significant share buybacks or major M&A activities directly altering the ownership structure, the company has actively pursued strategic partnerships to advance its therapy development. Leadership changes are also noted, with Dr. Donald deBethizy planning to retire from the Board of Directors following the Annual General Meeting on May 27, 2025. The company's trajectory is further bolstered by clinical successes, including the FDA approval of Vyvgart for CIDP and the anticipated April 2025 launch of a prefilled syringe formulation, both expected to fuel continued growth. The ambitious 'Vision 2030' plan, aiming to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates to Phase 3, provides a clear roadmap for future value creation and influences current arGEN-X ownership trends.

Institutional Investor Confidence

Institutional investors now collectively own over 60% of arGEN-X's stock. This significant stake reflects growing confidence in the company's market performance and future potential.

Strategic Growth Drivers

The FDA approval of Vyvgart for CIDP and the upcoming prefilled syringe formulation are key clinical catalysts. These advancements are expected to drive substantial growth in 2025 and beyond.

Financial Strength and Future Outlook

With preliminary full-year 2024 sales of $2.2 billion and Q2 2025 sales reaching $949 million, the company is well-positioned. Approximately $3.9 billion in cash reserves supports continued investment and a transition to sustainable profitability in 2025.

Visionary Long-Term Strategy

The 'Vision 2030' plan outlines ambitious goals, including treating 50,000 patients globally and securing 10 labeled indications. This strategic foresight guides the company's direction and potential for future value creation.

arGEN-X Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔